Historically, 99% of Alzheimer’s disease drugs to enter clinical trials have failed, yet Axovant Sciences (NASDAQ: AXON) believed it could design a phase 3 trial for its Alzheimer’s disease drug, intepirdine, that could overcome those stiff odds. Sadly, Axovant Sciences’ announced Tuesday morning that intepirdine, its lead product candidate, failed across the board to beat a placebo, delivering yet another setback to progress toward tackling this disease.